株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

世界の酵素阻害剤市場:欧州

Global Markets for Enzyme Inhibitors -- Focus on Europe

発行 BCC Research 商品コード 245533
出版日 ページ情報 英文 174 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.81円で換算しております。
Back to Top
世界の酵素阻害剤市場:欧州 Global Markets for Enzyme Inhibitors -- Focus on Europe
出版日: 2012年06月22日 ページ情報: 英文 174 Pages
担当者のコメント
当レポートは同出版社より発行されている「世界の酵素阻害剤市場(商品コード243850)」から欧州市場部分の情報を中心に抜粋して作成したレポートとなります。
概要

世界の酵素阻害剤市場は2010年に1,044億米ドル、2011年には1,046億米ドルの市場規模を記録しました。今後は4%の年平均成長率(CAGR)で推移し、2016年には約1,274億米ドルの規模に成長すると予測されています。欧州の酵素阻害剤市場は、2010年に320億米ドル、2011年には324億米ドルを記録しました。その後はCAGR3.6%で拡大し、2016年には387億米ドル近くに達する見通しです。同地域におけるキナーゼ阻害剤の売上は、2010年に92億米ドル、2011年には94億米ドルでした。その後、2016年までCAGR4.4%で拡大し、116億米ドルに達する見通しです。

当レポートでは、世界の酵素阻害剤市場の現状と見通しについて、欧州を中心に調査分析し、酵素の基礎情報、酵素阻害のメカニズム、酵素阻害剤のタイプと分類、新薬の申請・承認の動向、主要企業とその製品、阻害剤のタイプ・治療区分・市場成長予測(〜2016年)、主要製造業者の市場シェア、特許情報、主要企業のプロファイルなどをまとめ、概略以下の構成でお届けいたします。

第1章 イントロダクション

第2章 サマリー

第3章 概要

  • 定義
  • 酵素の構成
  • 活性化エネルギー
  • 特異性
  • 酵素基質結合
  • 酵素作用の諸条件
  • 酵素の分類
  • 酵素の実際の用途
  • 人間の身体と酵素の必要性
  • 酵素阻害剤とは
  • 酵素の阻害の理由
  • 酵素阻害剤の利用
  • 酵素阻害のメカニズム
  • 酵素阻害剤のタイプ
  • 酵素阻害剤の分類

第4章 法規制

  • 酵素阻害剤の新薬承認:2008-2011年
  • 酵素阻害剤の新薬申請
  • 酵素阻害剤のセーフティアラート:2008-2011年

第5章 酵素阻害剤の市場リーダーおよび製品

  • 主要製造業者・サプライヤー:プロトンポンプ阻害剤
  • 主要製造業者・サプライヤー:プロテアーゼ阻害剤
  • 主要製造業者・サプライヤー:プロテインキナーゼ阻害剤
  • 主要製造業者・サプライヤー:スタチン
  • 主要製造業者・サプライヤー:アロマターゼ阻害剤
  • 主要製造業者・サプライヤー:逆転写酵素阻害剤
  • 主要製造業者・サプライヤー:PED5阻害剤
  • 主要製造業者・サプライヤー:ノイラミニダーゼ阻害剤
  • 主要製造業者・サプライヤー:ACE阻害剤

第6章 新たな開発

  • 治験段階の新薬

第7章 世界市場

  • 市場分析
    • プロトンポンプ阻害剤
    • プロテアーゼ阻害剤
    • 逆転写酵素阻害剤
    • キナーゼ阻害剤
    • スタチン
    • アロマターゼ阻害剤
    • PED5阻害剤
    • ノイラミニダーゼ阻害剤
    • ACE阻害剤
  • 市場シェア
  • アプリケーション別市場
    • 心血管疾患
    • 胃腸疾患
    • AIDS
    • 肝炎
    • ED
    • その他
    • 世界市場における酵素阻害剤のシェア:アプリケーション別

第8章 欧州市場

  • 市場分析
    • プロトンポンプ阻害剤
    • プロテアーゼ阻害剤
    • 逆転写酵素阻害剤
    • キナーゼ阻害剤
    • スタチン
    • アロマターゼ阻害剤
    • PED5阻害剤
    • ノイラミニダーゼ阻害剤
    • ACE阻害剤
  • 市場シェア
    • プロトンポンプ阻害剤
    • プロテアーゼ阻害剤
    • 逆転写酵素阻害剤
    • キナーゼ阻害剤
    • スタチン
    • アロマターゼ阻害剤
    • PED5阻害剤
    • ノイラミニダーゼ阻害剤
    • ACE阻害剤
  • アプリケーション別市場
    • 心血管疾患
    • 胃腸疾患
    • AIDS
    • 肝炎
    • ED
    • その他

第9章 特許分析

  • 年別
  • タイプ別
  • 企業別
  • 国別
  • 申請者別

第10章 現況

  • 市場の状況
  • 酵素阻害剤市場の動向と課題

第11章 企業プロファイル

第12章 付録

図表

目次
Product Code: BIO106A

Abstract

REPORT HIGHLIGHTS

  • The global market for enzyme inhibitors was valued at $104.4 billion in 2010 and reached nearly $104.6 billion in 2011. This market is expected to rise at a compound annual growth rate (CAGR) of 4% and reach nearly $127.4 billion by 2016.
  • The European market for enzyme inhibitors was $32 billion in 2010, which rose to $32.4 billion in 2011. This sector is expected to rise at a CAGR of 3.6% and reach nearly $38.7 billion by 2016.
  • European sales of kinase inhibitors were $9.2 billion in 2010 and $9.4 billion in 2011. This segment is expected to grow at a CAGR of 4.4% and reach $11.6 billion by 2016.

image1

REPORT SCOPE

INTRODUCTION

STUDY GOALS AND OBJECTIVES

The overall goal of this study is to provide a comprehensive understanding of the current and future characteristics of the global market for enzyme inhibitors.

This report explores present and future strategies within the market for enzyme inhibitors, which includes proton pump inhibitors (PPIs), protease inhibitors, reverse transcriptase inhibitors, kinase inhibitors, statins, aromatase inhibitors, phosphodiesterase type 5 (PDE5) inhibitors, neuraminidase inhibitors, and angiotensin-converting enzyme (ACE) inhibitors. The improvements in the market and the setbacks and needs of the market are discussed in this report. The comparisons, usage, and advantages and disadvantages of different types of enzyme inhibitors are also discussed in this report.

A detailed analysis of the enzyme inhibitors industry structure has been conducted. Revenues are broken down by region. Sales figures are estimated for the five-year forecast period of this report, from 2011 to 2016.

Applications for enzyme inhibitors are also discussed in the report, with emphasis on the usage of the inhibitors in therapeutic categories and various disease sectors. The report also covers significant patents and their allotments in each category.

REASONS FOR DOING THE STUDY

Extensive research in the field of enzyme inhibitors has revealed their target-specific functionality in being able to provide therapeutic treatments for various chronic diseases. Modern industries have now begun to explore the advantages of enzyme inhibitors in their productions and processes. This has led to steady market growth for enzyme inhibitors.

Research and development (R&D) spending, along with increasing competition, patent expirations and new technologies, is directing this to a new level. Although, due to patent expirations, the overall revenue for the market has decreased slightly from 2009 to 2011, new advancements, new product launches and the changing lifestyle will cause the market to grow in the foreseeable future. This study looks at almost all the systems affected by these factors.

Acquisition strategies and collaborations by companies are also covered in this report. This study also discusses the strengths and weaknesses of each type/technology in light of the new technologies, growing competition and changing customer needs.

CONTRIBUTIONS OF THE STUDY AND INTENDED AUDIENCE

This report provides invaluable information to manufacturers and users of PPIs, protease inhibitors, reverse transcriptase inhibitors, kinase inhibitors, statins, aromatase inhibitors, PDE5 inhibitors, neuraminidase inhibitors, and ACE inhibitors. Pharmaceutical and biotechnology companies, research institutes, and physicians will find this study to be of interest.

SCOPE OF REPORT

The scope of this study encompasses enzyme inhibitors in the pharmaceutical and biotechnology industry. BCC Research analyzes each market and its applications, regulatory environment, technology involved, market projections and market share. Technological issues include the latest trends and developments. Emerging markets for enzyme inhibitors include countries such as India, China, Japan, Korea, Taiwan, Canada, Africa, Australia and New Zealand.

METHODOLOGY AND INFORMATION SOURCES

BCC conducted a comprehensive literature search, which included technical newsletters and journals. The data were collected through interviews and correspondence with technical experts manufacturing enzyme inhibitors. Projections were based on estimates such as the current number of end users, potential end users, mergers and acquisitions, and market trends.

Many companies within the industry were surveyed to obtain data for this study. Included were manufacturers and end users of enzyme inhibitors in therapeutic categories and various disease sectors industries. The data were carefully collected from various industry sources. BCC spoke with officials within the industry and consulted newsletters; company and product literature; and a host of technical articles, journals, indexes and abstracts. Exhaustive investigations of databases by key terminology were completed. In addition, the data were compiled from current financial, trade and government sources.

ANALYST CREDENTIALS

The study has been carried out by a team of professionals in the biotechnology industry. The project manager for this project is Shalini S. Dewan, who holds a master's degree in pharmaceutical chemistry and has more than 14 years of industry experience. Among the research topics she has covered are studies on compounds of potential pharmaceutical interest from ibuprofen and 2-naphthyl acetic acid. Dewan was awarded a Gold Medal by the prime minister of India for her work and has worked with top companies in India and in the U.S. Some of her other reports with BCC are Reagents for Chromatography; Spectroscopy, An Enduring Market; Advanced Drug Delivery Systems: Technologies and Global Markets; Orthopedic Drugs, Implants and Devices; Medical Imaging Reagents and Analysis Equipment; Pharmaceutical Regulatory Industry; The Dynamic Media, Sera and Reagent Market in Biotechnology; Contract Pharmaceutical Manufacturing, Research and Packaging: Global Markets; Chiral Technology: Global Markets; Autacoids and Related Drugs: Technologies and Global Markets; Contraceptives: Technologies and Global Markets; Liver Disease Treatments: The Global Market; Hormone Replacement Therapies and Other Hormone Therapies: Global Markets; Cardiovascular Medicine: Diagnostics, Drugs and Devices; and Cancer Therapies: Technologies and Global Markets.

The lead consultant for this project is Dr. Kapil A. Setia, who has a doctorate in life sciences. She has a number of research publications in her credit, including her thesis on "Studies on Phenotypic Variation, Clonal Propagation and Phyto-chemistry of Tinospora cordifolia (Willd.)," which was given an award of excellence.

Table of Contents

Chapter- 1: INTRODUCTION - Complimentary

  • STUDY GOALS AND OBJECTIVES
  • REASONS FOR DOING THE STUDY
  • CONTRIBUTIONS OF THE STUDY AND INTENDED AUDIENCE
  • SCOPE OF REPORT
  • METHODOLOGY AND INFORMATION SOURCES
  • ANALYST CREDENTIALS
  • RELATED REPORTS
  • BCC ON-LINE SERVICES
  • DISCLAIMER

Chapter- 2: SUMMARY

  • Table Summary : GLOBAL REVENUE OF ENZYME INHIBITORS MARKET, THROUGH 2016
  • Figure Summary : GLOBAL REVENUE OF ENZYME INHIBITORS MARKET, 2009-2016

Chapter- 3: OVERVIEW

  • DEFINITIONS
  • STRUCTURE OF ENZYMES
  • ACTIVATION ENERGY
  • SPECIFICITY
  • ENZYME SUBSTRATE INTERACTION
  • CONDITIONS OF ENZYME ACTION
  • CLASSIFICATION OF ENZYMES
  • REAL-LIFE APPLICATIONS OF ENZYMES
  • NEED FOR ENZYMES IN HUMAN BODY
  • WHAT ARE ENZYME INHIBITORS
  • WHY ENZYME INHIBITION
  • USE OF ENZYME INHIBITORS
  • MECHANISM OF ENZYME INHIBITION
  • TYPES OF ENZYME INHIBITORS
  • CLASSIFICATION OF ENZYME INHIBITORS

Chapter- 4: REGULATORY ASPECTS

  • Table 5 : NEW DRUG APPROVALS FOR ENZYME INHIBITORS, 2008-2011
  • Table 6 : NEW DRUG APPLICATIONS FOR ENZYME INHIBITORS
  • Table 7 : SAFETY ALERTS FOR ENZYME INHIBITORS, 2008-2011

Chapter- 5: MARKET LEADERS AND THEIR PRODUCTS FOR ENZYME INHIBITORS

  • Table 8 : LEADING MANUFACTURERS/SUPPLIERS OF PROTON PUMP INHIBITORS
  • Table 9 : LEADING MANUFACTURERS/SUPPLIERS OF PROTEASE INHIBITORS
  • Table 10 : LEADING MANUFACTURERS/SUPPLIERS OF KINASE INHIBITORS
  • Table 11 : LEADING MANUFACTURERS/SUPPLIERS OF STATINS
  • Table 12 : LEADING MANUFACTURERS/SUPPLIERS OF AROMATASE INHIBITORS
  • Table 13 : LEADING MANUFACTURERS/SUPPLIERS OF REVERSE TRANSCRIPTASE INHIBITORS
  • Table 14 : LEADING MANUFACTURERS/SUPPLIERS OF PED5 INHIBITORS
  • Table 15 : LEADING MANUFACTURERS/SUPPLIERS OF NEURAMINIDASE INHIBITORS
  • Table 16 : LEADING MANUFACTURERS/SUPPLIERS OF ACE INHIBITORS

Chapter- 6: NEW DEVELOPMENTS

  • NEW DRUGS IN CLINICAL TRIALS
  • Table 27 : NEW ENZYME INHIBITORS IN CLINICAL TRIALS

Chapter- 7: GLOBAL MARKETS

  • MARKET ANALYSIS
  • MARKET SHARES
  • MARKET BY APPLICATIONS
  • Table 28 : GLOBAL MARKET FOR ENZYME INHIBITORS, THROUGH 2016
  • Figure 1 : GLOBAL MARKET FOR ENZYME INHIBITORS, 2009-2016

Chapter- 8: MARKETS IN EUROPE

  • MARKET ANALYSIS
  • MARKET SHARES OF INDUSTRY LEADERS IN EUROPE
  • MARKET BY APPLICATIONS
  • Table 56 : EUROPEAN MARKET FOR ENZYME INHIBITORS, THROUGH 2016
  • Figure 29 : EUROPEAN MARKET FOR ENZYME INHIBITORS, 2009-2016

Chapter- 9: PATENT ANALYSIS9$303

  • PATENTS BY YEAR
  • PATENTS BY TYPE
  • PATENTS BY COMPANY
  • PATENTS BY COUNTRY
  • PATENTS BY ASSIGNEE
  • Table 83 : NUMBER OF SIGNIFICANT PATENTS BY YEAR, 2008-2012
  • Figure 56 : NUMBER OF PATENTS BY YEAR, 2008-2012
  • Figure 57 : NUMBER OF PATENTS BY YEAR, 2008 - 2012

Chapter- 10: CURRENT SITUATION

  • MARKET CONDITIONS
  • TRENDS AND ISSUES IN ENZYME INHIBITORS MARKET

Chapter- 11: COMPANY PROFILES

  • ABBOTT LABORATORIES
  • AMGEN INC.
  • ASTRAZENECA PLC
  • AUROBINDO PHARMA
  • BAYER HEALTHCARE PHARMACEUTICALS
  • BOEHRINGER INGELHEIM GMBH
  • BRISTOL-MYERS SQUIBB
  • CIPLA LTD.
  • DR. REDDY'S LABORATORIES LTD.
  • EISAI INC.
  • ELI LILLY & CO.
  • ENDO PHARMACEUTICALS
  • GILEAD SCIENCES INC.
  • GLAXOSMITHKLINE PLC
  • GLENMARK GENERICS LTD.
  • HETERO DRUGS LTD.
  • HOFFMAN-LA ROCHE LTD.
  • INCYTE CORP.
  • JOHNSON & JOHNSON
  • LUPIN PHARMACEUTICALS INC.
  • MERCK & CO. INC.
  • MERCK SERONO SA
  • MYLAN LABORATORIES INC.
  • MYLAN LABORATORIES LTD.
  • NOVARTIS AG
  • NOVARTIS NORTH AMERICA
  • OSI PHARMACEUTICALS LLC
  • PAR PHARMACEUTICAL COMPANIES INC.
  • PFIZER INC.
  • RANBAXY LABORATORIES LTD.
  • ROXANE LABORATORIES LTD.
  • SANDOZ
  • SANOFI-AVENTIS
  • SANTARUS INC.
  • SUN PHARMACEUTICALS
  • TAKEDA PHARMACEUTICAL CO. LTD.
  • TEVA PHARMACEUTICAL INDUSTRIES LTD.
  • VERTEX PHARMACEUTICALS
  • VIIV HEALTHCARE
  • WATSON PHARMACEUTICALS INC.

Chapter- 12: APPENDIX - ABBREVIATIONS

List of Tables

  • Summary Table : GLOBAL REVENUE OF ENZYME INHIBITORS MARKET, THROUGH 2016
  • Table 1 : CLASSIFICATION OF ENZYME INHIBITORS
  • Table 2 : HISTORY OF DEVELOPMENT OF STATINS
  • Table 3 : HISTORY OF DISCOVERY OF PROTEASE INHIBITORS
  • Table 4 : DEVELOPMENT OF ACE INHIBITORS
  • Table 5 : NEW DRUG APPROVALS FOR ENZYME INHIBITORS, 2008-2011
  • Table 6 : NEW DRUG APPLICATIONS FOR ENZYME INHIBITORS
  • Table 7 : SAFETY ALERTS FOR ENZYME INHIBITORS, 2008-2011
  • Table 8 : LEADING MANUFACTURERS/SUPPLIERS OF PROTON PUMP INHIBITORS
  • Table 9 : LEADING MANUFACTURERS/SUPPLIERS OF PROTEASE INHIBITORS
  • Table 10 : LEADING MANUFACTURERS/SUPPLIERS OF KINASE INHIBITORS
  • Table 11 : LEADING MANUFACTURERS/SUPPLIERS OF STATINS
  • Table 12 : LEADING MANUFACTURERS/SUPPLIERS OF AROMATASE INHIBITORS
  • Table 13 : LEADING MANUFACTURERS/SUPPLIERS OF REVERSE TRANSCRIPTASE INHIBITORS
  • Table 14 : LEADING MANUFACTURERS/SUPPLIERS OF PED5 INHIBITORS
  • Table 15 : LEADING MANUFACTURERS/SUPPLIERS OF NEURAMINIDASE INHIBITORS
  • Table 16 : LEADING MANUFACTURERS/SUPPLIERS OF ACE INHIBITORS
  • Table 17 : CLINICAL TRIALS ENZYME INHIBITORS
  • Table 18 : CLINICAL TRIALS OF STATINS
  • Table 19 : CLINICAL TRIALS FOR AROMATASE INHIBITORS
  • Table 20 : CLINICAL TRIALS FOR REVERSE TRANSCRIPTASE INHIBITORS
  • Table 21 : CLINICAL TRIALS FOR PROTEIN KINASE INHIBITORS
  • Table 22 : CLINICAL TRIALS FOR PDE5 INHIBITORS
  • Table 23 : CLINICAL TRIALS FOR PDE4 INHIBITORS
  • Table 24 : CLINICAL TRIALS FOR PROTEASE INHIBITORS
  • Table 25 : CLINICAL TRIALS FOR ACE INHIBITORS
  • Table 26 : CLINICAL TRIALS FOR PROTON PUMP INHIBITORS
  • Table 27 : NEW ENZYME INHIBITORS IN CLINICAL TRIALS
  • Table 28 : GLOBAL MARKET FOR ENZYME INHIBITORS, THROUGH 2016
  • Table 29 : GLOBAL MARKET FOR PROTON PUMP INHIBITORS, THROUGH 2016
  • Table 30 : GLOBAL MARKET FOR PROTEASE INHIBITORS, THROUGH 2016
  • Table 31 : GLOBAL MARKET FOR REVERSE TRANSCRIPTASE INHIBITORS, THROUGH 2016
  • Table 32 : GLOBAL MARKET FOR KINASE INHIBITORS, THROUGH 2016
  • Table 33 : GLOBAL MARKET FOR STATINS, THROUGH 2016
  • Table 34 : GLOBAL MARKET FOR AROMATASE INHIBITORS, THROUGH 2016
  • Table 35 : GLOBAL MARKET FOR PDE5 INHIBITORS, THROUGH 2016
  • Table 36 : GLOBAL MARKET FOR NEURAMINIDASE INHIBITORS, THROUGH 2016
  • Table 37 : GLOBAL MARKET FOR ACE INHIBITORS, THROUGH 2016
  • Table 38 : PROTON PUMP INHIBITOR MARKET SHARES BY REGION, 2010
  • Table 39 : PROTEASE INHIBITOR MARKET SHARES BY REGION, 2010
  • Table 40 : REVERSE TRANSCRIPTASE INHIBITOR MARKET SHARES BY REGION, 2010
  • Table 41 : KINASE INHIBITOR MARKET SHARES BY REGION, 2010
  • Table 42 : STATINS INHIBITOR MARKET SHARES BY REGION, 2010
  • Table 43 : AROMATASE INHIBITOR MARKET SHARES BY REGION, 2010
  • Table 44 : PDE5 INHIBITOR MARKET SHARES BY REGION, 2010
  • Table 45 : NEURAMINIDASE INHIBITOR MARKET SHARES BY REGION, 2010
  • Table 46 : ACE INHIBITOR MARKET SHARES BY REGION, 2010
  • Table 47 : GLOBAL ENZYME INHIBITORS MARKET BY THERAPEUTIC CATEGORIES/ DISEASE SECTORS, THROUGH 2016
  • Table 48 : GLOBAL MARKET FOR ENZYME INHIBITORS IN CARDIOVASCULAR DISEASE, THROUGH 2016
  • Table 49 : GLOBAL MARKET OF ENZYME INHIBITORS IN GASTROINTESTINAL DISEASE, THROUGH 2016
  • Table 50 : GLOBAL MARKET OF ENZYME INHIBITORS IN HIV/AIDS, THROUGH 2016
  • Table 51 : GLOBAL MARKET OF ENZYME INHIBITORS IN HEPATITIS, THROUGH 2016
  • Table 52 : GLOBAL MARKET OF ENZYME INHIBITORS IN VARIOUS CANCERS, THROUGH 2016
  • Table 53 : GLOBAL MARKET OF ENZYME INHIBITORS IN ERECTILE DYSFUNCTION, THROUGH 2016
  • Table 54 : GLOBAL MARKET OF ENZYME INHIBITORS IN OTHER SECTORS, THROUGH 2016
  • Table 55 : GLOBAL MARKET SHARE OF ENZYME INHIBITORS BY APPLICATION, 2010
  • Table 56 : EUROPEAN MARKET FOR ENZYME INHIBITORS, THROUGH 2016
  • Table 57 : EUROPEAN MARKET FOR PROTON PUMP INHIBITORS, THROUGH 2016
  • Table 58 : EUROPEAN MARKET FOR PROTEASE INHIBITORS, THROUGH 2016
  • Table 59 : EUROPEAN MARKET FOR REVERSE TRANSCRIPTASE INHIBITORS, THROUGH 2016
  • Table 60 : EUROPEAN MARKET FOR KINASE INHIBITORS, THROUGH 2016
  • Table 61 : EUROPEAN MARKET FOR STATINS, THROUGH 2016
  • Table 62 : EUROPEAN MARKET FOR AROMATASE INHIBITORS, THROUGH 2016
  • Table 63 : EUROPEAN MARKET FOR PDE5 INHIBITORS, THROUGH 2016
  • Table 64 : EUROPEAN MARKET FOR NEURAMINIDASE INHIBITORS, THROUGH 2016
  • Table 65 : EUROPEAN MARKET FOR ACE INHIBITORS, THROUGH 2016
  • Table 66 : EUROPEAN MARKET SHARES OF PROTON PUMP INHIBITOR MANUFACTURERS, 2010
  • Table 67 : EUROPEAN MARKET SHARES OF PROTEASE INHIBITOR MANUFACTURERS, 2010
  • Table 68 : EUROPEAN MARKET SHARES OF KINASE INHIBITOR MANUFACTURERS, 2010
  • Table 69 : EUROPEAN MARKET SHARES OF STATINS MANUFACTURERS, 2010
  • Table 70 : EUROPEAN MARKET SHARES OF AROMATASE INHIBITOR MANUFACTURERS, 2010
  • Table 71 : EUROPEAN MARKET SHARES OF REVERSE TRANSCRIPTASE INHIBITOR MANUFACTURERS, 2010
  • Table 72 : EUROPEAN MARKET SHARES OF PDE5 INHIBITOR MANUFACTURERS, 2010
  • Table 73 : EUROPEAN MARKET SHARES OF NEURAMINIDASE INHIBITOR MANUFACTURERS, 2010
  • Table 74 : EUROPEAN MARKET SHARES OF ACE INHIBITOR MANUFACTURERS, 2010
  • Table 75 : EUROPEAN ENZYME INHIBITORS MARKET BY THERAPEUTIC CATEGORIES/DISEASE SECTORS, THROUGH 2016
  • Table 76 : EUROPEAN MARKET OF ENZYME INHIBITORS IN CARDIOVASCULAR DISEASE, THROUGH 2016
  • Table 77 : EUROPEAN MARKET OF ENZYME INHIBITORS IN GASTROINTESTINAL DISEASE, THROUGH 2016
  • Table 78 : EUROPEAN MARKET OF ENZYME INHIBITORS IN HIV/AIDS, THROUGH 2016
  • Table 79 : EUROPEAN MARKET OF ENZYME INHIBITORS IN VARIOUS CANCERS, THROUGH 2016
  • Table 80 : EUROPEAN MARKET OF ENZYME INHIBITORS IN HEPATITIS, THROUGH 2016
  • Table 81 : EUROPEAN MARKET OF ENZYME INHIBITORS IN ERECTILE DYSFUNCTION, THROUGH 2016
  • Table 82 : EUROPEAN MARKET OF ENZYME INHIBITORS IN OTHER DISEASES, THROUGH 2016
  • Table 83 : NUMBER OF SIGNIFICANT PATENTS BY YEAR, 2008-2012
  • Table 84 : PATENTS BY TYPE FOR ENZYME INHIBITORS, 2008-2012
  • Table 85 : NUMBER OF U.S. PATENTS BY COMPANY FOR ENZYME INHIBITORS, 2008-2012
  • Table 86 : TOTAL NUMBER OF U.S. PATENTS BY COUNTRY FOR ENZYME INHIBITORS, 2008-2012
  • Table 87 : PATENT SHARES BY COUNTRY FOR INDUSTRIAL ENZYMES, 2008 - 2012
  • Table 88 : PATENTS BY TYPE FOR INDUSTRIAL ENZYMES, 2008-2012

List of Figures

  • Summary Figure : GLOBAL REVENUE OF ENZYME INHIBITORS MARKET, 2009-2016
  • Figure 1 : GLOBAL MARKET FOR ENZYME INHIBITORS, 2009-2016
  • Figure 2 : GLOBAL MARKET FOR PROTON PUMP INHIBITORS, 2009-2016
  • Figure 3 : GLOBAL MARKET FOR PROTEASE INHIBITORS, 2009-2016
  • Figure 4 : GLOBAL MARKET FOR REVERSE TRANSCRIPTASE INHIBITORS, 2009-2016
  • Figure 5 : GLOBAL MARKET FOR KINASE INHIBITORS, 2009-2016
  • Figure 6 : GLOBAL MARKET FOR STATINS, 2009-2016
  • Figure 7 : GLOBAL MARKET FOR AROMATASE INHIBITORS, 2009-2016
  • Figure 8 : GLOBAL MARKET FOR PDE5 INHIBITORS, 2009-2016
  • Figure 9 : GLOBAL MARKET FOR NEURAMINIDASE INHIBITORS, 2009-2016
  • Figure 10 : GLOBAL MARKET FOR ACE INHIBITORS, 2009-2016
  • Figure 11 : PROTON PUMP INHIBITOR MARKET SHARES BY REGION, 2010
  • Figure 12 : PROTEASE INHIBITOR MARKET SHARES BY REGION, 2010
  • Figure 13 : REVERSE TRANSCRIPTASE INHIBITOR MARKET SHARES BY REGION, 2010
  • Figure 14 : KINASE INHIBITOR MARKET SHARES BY REGION, 2010
  • Figure 15 : STATINS INHIBITOR MARKET SHARES BY REGION, 2010
  • Figure 16 : AROMATASE INHIBITOR MARKET SHARES BY REGION, 2010
  • Figure 17 : PDE5 INHIBITOR MARKET SHARES BY REGION, 2010
  • Figure 18 : NEURAMINIDASE INHIBITOR MARKET SHARES BY REGION, 2010
  • Figure 19 : ACE INHIBITOR MARKET SHARES BY REGION, 2010
  • Figure 20 : GLOBAL ENZYME INHIBITORS MARKET BY THERAPEUTIC CATEGORIES/ DISEASE SECTORS, 2009-2016
  • Figure 21 : GLOBAL MARKET OF ENZYME INHIBITORS IN CARDIOVASCULAR DISEASE, 2009-2016
  • Figure 22 : GLOBAL MARKET OF ENZYME INHIBITORS IN GASTROINTESTINAL DISEASE, 2009-2016
  • Figure 23 : GLOBAL MARKET OF ENZYME INHIBITORS IN HIV/AIDS, 2009-2016
  • Figure 24 : GLOBAL MARKET OF ENZYME INHIBITORS IN HEPATITIS, 2009-2016
  • Figure 25 : GLOBAL MARKET OF ENZYME INHIBITORS IN VARIOUS CANCERS, 2009-2016
  • Figure 26 : GLOBAL MARKET OF ENZYME INHIBITORS IN ERECTILE DYSFUNCTION, 2009-2016
  • Figure 27 : GLOBAL MARKET OF ENZYME INHIBITORS IN OTHER SECTORS, 2009-2016
  • Figure 28 : GLOBAL MARKET SHARE OF TECHNICAL ENZYMES, 2010
  • Figure 29 : EUROPEAN MARKET FOR ENZYME INHIBITORS, 2009-2016
  • Figure 30 : EUROPEAN MARKET FOR PROTON PUMP INHIBITORS, 2009-2016
  • Figure 31 : EUROPEAN MARKET FOR PROTEASE INHIBITORS, 2009-2016
  • Figure 32 : EUROPEAN MARKET FOR REVERSE TRANSCRIPTASE INHIBITORS, 2009-2016
  • Figure 33 : EUROPEAN MARKET FOR KINASE INHIBITORS, 2009-2016
  • Figure 34 : EUROPEAN MARKET FOR STATINS, 2009-2016
  • Figure 35 : EUROPEAN MARKET FOR AROMATASE INHIBITORS, 2009-2016
  • Figure 36 : EUROPEAN MARKET FOR PDE5 INHIBITORS, THROUGH 2016
  • Figure 37 : EUROPEAN MARKET FOR NEURAMINIDASE INHIBITORS, 2009-2016
  • Figure 38 : EUROPEAN MARKET FOR ACE INHIBITORS, 2009-2016
  • Figure 39 : EUROPEAN MARKET SHARES OF PROTON PUMP INHIBITOR MANUFACTURERS, 2010
  • Figure 40 : EUROPEAN MARKET SHARES OF PROTEASE INHIBITORS MANUFACTURERS, 2010
  • Figure 41 : EUROPEAN MARKET SHARES OF KINASE INHIBITORS MANUFACTURERS, 2010
  • Figure 42 : EUROPEAN MARKET SHARES OF STATINS MANUFACTURERS, 2010
  • Figure 43 : EUROPEAN MARKET SHARES OF AROMATASE INHIBITOR MANUFACTURERS, 2010
  • Figure 44 : EUROPEAN MARKET SHARES OF REVERSE TRANSCRIPTASE MANUFACTURERS, 2010
  • Figure 45 : EUROPEAN MARKET SHARES OF PDE5 INHIBITOR MANUFACTURERS, 2010
  • Figure 46 : EUROPEAN MARKET SHARES OF NEURAMINIDASE INHIBITOR MANUFACTURERS, 2010
  • Figure 47 : EUROPEAN MARKET SHARES OF ACE INHIBITOR MANUFACTURERS, 2010
  • Figure 48 : EUROPEAN ENZYME INHIBITORS MARKET BY THERAPEUTIC CATEGORIES/DISEASE SECTORS, 2009-2016
  • Figure 49 : EUROPEAN MARKET OF ENZYME INHIBITORS IN CARDIOVASCULAR DISEASE, 2009-2016
  • Figure 50 : EUROPEAN MARKET OF ENZYME INHIBITORS IN GASTROINTESTINAL DISEASE, 2009-2016
  • Figure 51 : EUROPEAN MARKET OF ENZYME INHIBITORS IN HIV/AIDS, 2009-2016
  • Figure 52 : EUROPEAN MARKET OF ENZYME INHIBITORS IN CANCER, 2009-2016
  • Figure 53 : EUROPEAN MARKET OF ENZYME INHIBITORS IN HEPATITIS, 2009-2016
  • Figure 54 : EUROPEAN MARKET OF ENZYME INHIBITORS IN ERECTILE DYSFUNCTION, 2009-2016
  • Figure 55 : EUROPEAN MARKET OF ENZYME INHIBITORS IN OTHER DISEASES, 2009-2016
  • Figure 56 : NUMBER OF PATENTS BY YEAR, 2008-2012
  • Figure 57 : NUMBER OF PATENTS BY YEAR, 2008 - 2012
  • Figure 58 : PATENTS BY TYPE FOR ENZYME INHIBITORS, 2008 - 2012
  • Figure 59 : TOTAL NUMBER OF U.S. PATENTS BY COUNTRY FOR ENZYME INHIBITORS, 2008 - 2012
  • Figure 60 : PATENT SHARES BY COUNTRY FOR ENZYME INHIBITORS, 2008 - 2012
  • Figure 61 : PATENTS BY ASSIGNEE FOR INDUSTRIAL ENZYMES, 2008 - 2012
Back to Top